Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Center for iPS Cell Research and Application (CiRA), Kyoto University and Dainippon Sumitomo Pharma (DSP) have entered into a five year research collaboration to develop a treatment for a rare intractable disease caused by genetic mutation.
Subscribe to our email newsletter
CiRA and DSP aim to utilize induced pluripotent stem cells (iPS cells) for idenfying the pathognomonic mechanism of the disease, identify the most disease-specific target molecule from various pathological changes of signal transduction, and screen specific inhibitors against the signal pathway.
Under the agreement, DSP will synthesize, investigate and optimize candidate compounds, and develop the treatment for the disease found through the joint research.